StreetInsider.com News Articles

Form 8-K PepGen Inc. For: Aug 06

Thu, 06 Aug 2026 07:41:00 -0400

si-local-file:///var/storage/secattach/20260806/26878936.html

Form 8-K PepGen Inc. For: Aug 06

Thu, 06 Aug 2026 07:41:00 -0400

si-local-file:///var/storage/secattach/20260806/26878936.html

PepGen Inc. (PEPG) Tops Q2 EPS by 3c

Thu, 06 Aug 2026 07:35:03 -0400

PepGen Inc. (NASDAQ: PEPG) reported Q2 EPS of ($0.26), $0.03 better than the analyst estimate of ($0.29).

For earnings history and earnings-related data on PepGen Inc. (PEPG) click here.

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 06 Aug 2026 07:32:00 -0400

– DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg to 10 mg/kg –

– 10 mg/kg FREEDOM2-DM1 cohort fully enrolled, with 7 of 8 participants having completed dosing; data expected in November –

– Results from 12.5 mg/kg FREEDOM2-DM1 cohort expected in 1H 2027 –

– Well-funded with $117.2M of cash as of June 30, 2026, sufficient to fund operations into the fourth quarter of 2027 –

BOSTON--(BUSINESS WIRE)-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 06 Aug 2026 07:32:00 -0400

– DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg to 10 mg/kg –

– 10 mg/kg FREEDOM2-DM1 cohort fully enrolled, with 7 of 8 participants having completed dosing; data expected in November –

– Results from 12.5 mg/kg FREEDOM2-DM1 cohort expected in 1H 2027 –

– Well-funded with $117.2M of cash as of June 30, 2026, sufficient to fund operations into the fourth quarter of 2027 –

BOSTON--(BUSINESS WIRE)-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 06 Aug 2026 07:32:00 -0400

– DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg to 10 mg/kg –

– 10 mg/kg FREEDOM2-DM1 cohort fully enrolled, with 7 of 8 participants having completed dosing; data expected in November –

– Results from 12.5 mg/kg FREEDOM2-DM1 cohort expected in 1H 2027 –

– Well-funded with $117.2M of cash as of June 30, 2026, sufficient to fund operations into the fourth quarter of 2027 –

BOSTON--(BUSINESS WIRE)-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 06 Aug 2026 07:32:00 -0400

– DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg to 10 mg/kg –

– 10 mg/kg FREEDOM2-DM1 cohort fully enrolled, with 7 of 8 participants having completed dosing; data expected in November –

– Results from 12.5 mg/kg FREEDOM2-DM1 cohort expected in 1H 2027 –

– Well-funded with $117.2M of cash as of June 30, 2026, sufficient to fund operations into the fourth quarter of 2027 –

BOSTON--(BUSINESS WIRE)-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 06 Aug 2026 07:32:00 -0400

– DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg to 10 mg/kg –

– 10 mg/kg FREEDOM2-DM1 cohort fully enrolled, with 7 of 8 participants having completed dosing; data expected in November –

– Results from 12.5 mg/kg FREEDOM2-DM1 cohort expected in 1H 2027 –

– Well-funded with $117.2M of cash as of June 30, 2026, sufficient to fund operations into the fourth quarter of 2027 –

BOSTON--(BUSINESS WIRE)-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 06 Aug 2026 07:32:00 -0400

– DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg to 10 mg/kg –

– 10 mg/kg FREEDOM2-DM1 cohort fully enrolled, with 7 of 8 participants having completed dosing; data expected in November –

– Results from 12.5 mg/kg FREEDOM2-DM1 cohort expected in 1H 2027 –

– Well-funded with $117.2M of cash as of June 30, 2026, sufficient to fund operations into the fourth quarter of 2027 –

BOSTON--(BUSINESS WIRE)-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 06 Aug 2026 07:32:00 -0400

– DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg to 10 mg/kg –

– 10 mg/kg FREEDOM2-DM1 cohort fully enrolled, with 7 of 8 participants having completed dosing; data expected in November –

– Results from 12.5 mg/kg FREEDOM2-DM1 cohort expected in 1H 2027 –

– Well-funded with $117.2M of cash as of June 30, 2026, sufficient to fund operations into the fourth quarter of 2027 –

BOSTON--(BUSINESS WIRE)-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 06 Aug 2026 07:32:00 -0400

– DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg to 10 mg/kg –

– 10 mg/kg FREEDOM2-DM1 cohort fully enrolled, with 7 of 8 participants having completed dosing; data expected in November –

– Results from 12.5 mg/kg FREEDOM2-DM1 cohort expected in 1H 2027 –

– Well-funded with $117.2M of cash as of June 30, 2026, sufficient to fund operations into the fourth quarter of 2027 –

BOSTON--(BUSINESS WIRE)-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 06 Aug 2026 07:32:00 -0400

– DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg to 10 mg/kg –

– 10 mg/kg FREEDOM2-DM1 cohort fully enrolled, with 7 of 8 participants having completed dosing; data expected in November –

– Results from 12.5 mg/kg FREEDOM2-DM1 cohort expected in 1H 2027 –

– Well-funded with $117.2M of cash as of June 30, 2026, sufficient to fund operations into the fourth quarter of 2027 –

BOSTON--(BUSINESS WIRE)-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 06 Aug 2026 07:32:00 -0400

– DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg to 10 mg/kg –

– 10 mg/kg FREEDOM2-DM1 cohort fully enrolled, with 7 of 8 participants having completed dosing; data expected in November –

– Results from 12.5 mg/kg FREEDOM2-DM1 cohort expected in 1H 2027 –

– Well-funded with $117.2M of cash as of June 30, 2026, sufficient to fund operations into the fourth quarter of 2027 –

BOSTON--(BUSINESS WIRE)-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 06 Aug 2026 07:32:00 -0400

– DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg to 10 mg/kg –

– 10 mg/kg FREEDOM2-DM1 cohort fully enrolled, with 7 of 8 participants having completed dosing; data expected in November –

– Results from 12.5 mg/kg FREEDOM2-DM1 cohort expected in 1H 2027 –

– Well-funded with $117.2M of cash as of June 30, 2026, sufficient to fund operations into the fourth quarter of 2027 –

BOSTON--(BUSINESS WIRE)-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 06 Aug 2026 07:32:00 -0400

– DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg to 10 mg/kg –

– 10 mg/kg FREEDOM2-DM1 cohort fully enrolled, with 7 of 8 participants having completed dosing; data expected in November –

– Results from 12.5 mg/kg FREEDOM2-DM1 cohort expected in 1H 2027 –

– Well-funded with $117.2M of cash as of June 30, 2026, sufficient to fund operations into the fourth quarter of 2027 –

BOSTON--(BUSINESS WIRE)-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing

Form 10-Q PepGen Inc. For: Jun 30

Thu, 06 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260806/26878839.html

Form 10-Q PepGen Inc. For: Jun 30

Thu, 06 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260806/26878839.html

PepGen advances DM1 drug to highest dose after safety review

Thu, 06 Aug 2026 07:30:24 -0400

PepGen Inc. (Nasdaq: PEPG) said an independent Data and Safety Monitoring Board (DSMB) has recommended advancing its Phase 2 FREEDOM2-DM1 study of PGN-EDODM1 into the third and highest dose cohort of 12.5 mg/kg, with no changes to the study protocol.

The recommendation followed a review of safety data from the fully enrolled 10 mg/kg cohort and an open-label extension (OLE) study. The DSMB also recommended escalating doses in the OLE from 5 mg/kg to 10 mg/kg.

PGN-EDODM1 is an investigational therapy being studied for the treatment of myotonic dystrophy type 1 (DM1). The company said no serious adverse events, dose-limiting toxicities, or

PepGen advances DM1 drug to highest dose after safety review

Thu, 06 Aug 2026 07:30:24 -0400

PGN-EDODM1 is an investigational therapy being studied for the treatment of myotonic dystrophy type 1 (DM1). The company said no serious adverse events, dose-limiting toxicities, or

PepGen advances DM1 drug to highest dose after safety review

Thu, 06 Aug 2026 07:30:24 -0400

PGN-EDODM1 is an investigational therapy being studied for the treatment of myotonic dystrophy type 1 (DM1). The company said no serious adverse events, dose-limiting toxicities, or

PepGen advances DM1 drug to highest dose after safety review

Thu, 06 Aug 2026 07:30:24 -0400

PGN-EDODM1 is an investigational therapy being studied for the treatment of myotonic dystrophy type 1 (DM1). The company said no serious adverse events, dose-limiting toxicities, or

PepGen advances DM1 drug to highest dose after safety review

Thu, 06 Aug 2026 07:30:24 -0400

PGN-EDODM1 is an investigational therapy being studied for the treatment of myotonic dystrophy type 1 (DM1). The company said no serious adverse events, dose-limiting toxicities, or

PepGen advances DM1 drug to highest dose after safety review

Thu, 06 Aug 2026 07:30:24 -0400

PGN-EDODM1 is an investigational therapy being studied for the treatment of myotonic dystrophy type 1 (DM1). The company said no serious adverse events, dose-limiting toxicities, or

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

Thu, 06 Aug 2026 07:30:00 -0400

– DSMB also recommended dose escalation in FREEDOM-OLE from 5 mg/kg to 10 mg/kg –

BOSTON--(BUSINESS WIRE)-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that an independent Data and Safety Monitoring Board (DSMB) has recommended advancing the ongoing Phase 2 FREEDOM2-DM1 study evaluating PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) into the third and highest multiple ascending dose (MAD) cohort of 12.5 mg/kg, with no recommended changes to the study protocol. The

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

Thu, 06 Aug 2026 07:30:00 -0400

– DSMB also recommended dose escalation in FREEDOM-OLE from 5 mg/kg to 10 mg/kg –